Aofie Regan, Director of Charitable Programmes and Impact at GOSH's Children's Charity, describes the research that happens there, which is transparently on display for the public to see from the street. In addition to do work directly there that might not be driven forward on its own, they also recently initiated a clinical trials funding programme.

CEO Mohit Rawat discusses the deal and the scientific rationale for N-myristoyltransferase inhibitor (NMTi) payloads.

He discusses learnings from the company's previous data release in early June and how he believes the new data presented gives investors a fuller picture of the efficacy and safety profile of the therapy. He discusses next steps from a regulatory and business standpoint, clarifies a key point of investor confusion, and also provides an update on the company's Crohn's trial.

Co-Founder and CEO Nathaniel Wang describes the biology, which is designed to be more durable, tolerable, and offer less frequent dosing. The lead internal program is a rabies vaccine, and there is early work on mono, RSV/hMPV/PIV, gout, and a cancer vaccine platform. Coverage brought to you by

CEO Nancy Whiting walks us through the biology of SH2 and the potential breadth of it as a therapeutics approach (there are 120 SH2 domains). The lead STAT6 program is in healthy volunters, and the company is also working on a BTK. Plus, her thoughts on HHS's new initiative to speed up clinical trials in the United States. Chapters Her thoughts on HHS's new trials initiative - 2:39 Recludix's work on SH2 - 6:51 Coverage brought to you by

John Hood, the successful biotech entrepreneur and Co-Founder and CEO of Endeavor, describes the biological hypothesis for Hedgehog inhibition in IPF and why he thinks ENV-101 is the right asset for it. It is currently in a phase 2b that will read towards the end of the year, and he believes the trial can show more than just a slowing of the disease. Coverage brought to you by

Founder & CEO Beth Hoffman describes how Origami's platform is different than other degrades like PROTACs, and how it specifically is designed to clear the mutant huntingtin protein. Plus, details on a global collaboration announced earlier this year with Ipsen. Coverage brought to you by

CEO Sulagna Bhattacharya describes the science behind this, which is gene agnostic, and the work the company is going to develop it and seek approvals both in Japan and the United States.

CEO David Goldstein, a geneticist, describes his frustration with patient care when medicines were lacking rare genetic diseases, and how it motivated him to embark on drug development. Actio's lead program targets KCNT-1 and is in the clinic - preclinical animal work showed that inhibiting the target worked well, and that it may be less of a developmental condition. Coverage brought to you by

CEO Fred Aslan walks us through this unique program and its potential advantages, which include that it can be administered in the community setting and can also be redosed if necessary. A 350 patient randomized registration trial in rheumatoid arthritis will be underway this year. Coverage brought to you by

Chair and CEO Judy Chou describes the science behind the target (this is the company's second generation molecule), and discusses the current clinical program in UC. She believes they have a "best in disease outcome" medicine and says they have talked to all the key players in I&I regarding a potential collaboration. Coverage brought to you by

CEO Mohit Trikha describes the idea behind this approach, which in many ways is the opposite of what many ADC developers have been working on. The lead programs target PTK7 and CEACAM5. Coverage brought to you by

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.

CEO Paul Hastings describes his opinion of the benefits of an NK cell approach over T-cells, and discusses the work Nkarta has done to get to a high dose that should tell a clear story of the profile of this by year end. Coverage brought to you by

CEO Dannielle Appelhans describes how the platform works and how the company chose to focus on type 1 diabetes at this time. COUR also has partnerships with Takeda and Genentech. Coverage brought to you by

Founder & CEO Viswa Colluru describes the platform and how he believes it is differentiated from other AI discovery platforms Plus, discussing the lead program and why he believes there is ample room to meet unmet need in the large atopic dermatitis population even with big medicines on the market. Coverage brought to you by

President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology. Coverage brought to you by